Peyman Hadji MD

Prof. Peyman Hadji obtained his medical degree from the University of Frankfurt, Germany, in 1990, and went on to complete his postgraduate training in obstetrics and gynaecology at the Hamburg Institute of Endocrinology and Reproductive Medicine and the Philipps-University of Marburg, where he received his PD in 2001. In June 2006, he was appointed as a full Professor of Medicine at Philipps-University of Marburg. From 2014-2018, Dr. Hadji was the head of the department of bone oncology, endocrinology, and reproductive medicine at the Krankenhaus Nordwest in Frankfurt, Germany. Since October 2018, Dr. Hadji has been the head of the Frankfurt Centre of Bone Health. His current research interest is on the management of women with breast cancer, with a special focus on cancer-induced bone loss (CIBL), as well as studies on side-effect management in cancer therapies and outcome research. He is the first author of a recent practical guidance for the management of aromatase inhibitor-associated bone loss of seven international societies.

Dr. Hadji is also a co-author of the ESMO 2021 practice guidelines on bone health in cancer patients. He is additionally a co-author of the guidance on the use of bisphosphonates in solid tumours, a consensus recommendation from the second Cambridge conference on advancing treatment for metastatic bone cancer, and a clinical experience and treatment recommendation on aromatase inhibitor-induced arthralgia. In addition to this, Dr. Hadji has performed a number of studies on compliance and persistence in oncology and osteoporotic therapies, and is involved in several clinical studies on different pharmacological interventions for osteoporosis, including bisphosphonates, denosumab, parathyroid hormones, raloxifene, hormone therapy, and tamoxifen - in collaboration with a number of national and international centres.

Dr. Hadji is a co-author of the ESMO clinical practice guideline for bone health in cancer patients, the German S-III guidelines for the diagnosis and treatment of breast cancer (DGGG), the German S-III guidelines for ONJ (DGMK), the German Osteoporosis guidelines (DVO), the use of HRT in postmenopausal women (DGGG), as well as the German guidelines on hormonal contraception (DGGG). Currently, Dr. Hadji is the vice president of the Dachverband Osteologie (DVO) and a board member of the International Cancer and Bone Society (CABS) as well as the German Menopause Society (DMG). He is additionally an active member of several oncology and osteoporosis societies with a special interest in the diagnosis and treatment of bone oncology in women with breast cancer. He has published over 300 peer-reviewed articles and book chapters in these fields. His editorial activities extend to editor-in-chief of the Journal of Bone Oncology (IF 4.4) and refereeing for a number of national and international journals.